Cencora, Inc. (COR) Latest Company News

Sep 4, 2026, 14:56 UTC
Cencora (COR) launched CGT Enablement, a service to help health systems build and scale cell and gene therapy programs with financial, operational, and access support.
Source:
- zacks.com
Sep 2, 2026, 12:30 UTC
Cencora, through its Accelerate Pharmacy Solutions, launched Cell and Gene Therapy Enablement, a service to help health systems evaluate, build, and scale cell and gene therapy programs.
Source:
- businesswire.com
Aug 22, 2026, 07:10 UTC
Advisors Capital Management LLC disclosed a new minority stake in Cencora, Inc. by purchasing 2,644 shares valued at approximately $748,000, according to a Form 13F filing.
Source:
- defenseworld.net
Aug 14, 2026, 00:00 UTC
Lorence H. Kim, M.D. resigned from the Board of Directors of Cencora, Inc., effective August 13, 2026.
Aug 6, 2026, 11:05 UTC
Cencora repurchased $1 billion of its shares during the fiscal 2026 third quarter.
Source:
- marketbeat.com
Aug 5, 2026, 00:00 UTC
Cencora, Inc. amended its receivables securitization facility.
Aug 5, 2026, 00:00 UTC
Cencora, Inc. amended its multi-currency senior unsecured revolving credit facility, increasing aggregate commitments from $5.5 billion to $7.0 billion and extending maturity to July 2031.
Aug 5, 2026, 00:00 UTC
Cencora, Inc. reported Q3 2026 GAAP revenue of $84.8 billion, GAAP diluted EPS of $3.94, and adjusted diluted EPS of $4.48, with net income attributable to Cencora of $764 million.
Source:
Jul 20, 2026, 10:30 UTC
International Paper appointed Katherine Collins and Lori J Ryerkerk to its board, effective 1 October 2026.
Source:
- finance.yahoo.com
Jun 18, 2026, 15:36 UTC
Cencora launched an enhanced Nucleus solution for specialty practices, with a pilot underway across more than 20 physician practice sites.
Source:
- zacks.com
Jun 17, 2026, 12:00 UTC
Cencora launched a multi-site pilot of its enhanced Nucleus inventory management solution for specialty physician practices.
Source:
- businesswire.com
Jun 15, 2026, 00:00 UTC
Silvana Battaglia will retire as Executive Vice President and Chief Human Resources Officer of Cencora, Inc., effective July 12, 2026.

COR

Cencora (COR) launched CGT Enablement, a service to help health systems build and scale cell and gene therapy programs with financial, operational, and access support.

Cencora, through its Accelerate Pharmacy Solutions, launched Cell and Gene Therapy Enablement, a service to help health systems evaluate, build, and scale cell and gene therapy programs.

Advisors Capital Management LLC disclosed a new minority stake in Cencora, Inc. by purchasing 2,644 shares valued at approximately $748,000, according to a Form 13F filing.

Lorence H. Kim, M.D. resigned from the Board of Directors of Cencora, Inc., effective August 13, 2026.

Cencora repurchased $1 billion of its shares during the fiscal 2026 third quarter.

Cencora, Inc. amended its receivables securitization facility.

Cencora, Inc. amended its multi-currency senior unsecured revolving credit facility, increasing aggregate commitments from $5.5 billion to $7.0 billion and extending maturity to July 2031.

Cencora, Inc. reported Q3 2026 GAAP revenue of $84.8 billion, GAAP diluted EPS of $3.94, and adjusted diluted EPS of $4.48, with net income attributable to Cencora of $764 million.

International Paper appointed Katherine Collins and Lori J Ryerkerk to its board, effective 1 October 2026.

Cencora launched an enhanced Nucleus solution for specialty practices, with a pilot underway across more than 20 physician practice sites.

Cencora launched a multi-site pilot of its enhanced Nucleus inventory management solution for specialty physician practices.

Silvana Battaglia will retire as Executive Vice President and Chief Human Resources Officer of Cencora, Inc., effective July 12, 2026.